GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Ertapenem (Invanz)

Local RX List renal extractBase record retrieved 2026-09-05See the evidence for this drug5 sources available - open source summaries, references and comparisons

Invanz

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (5)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

2 additional source qualifications - review before use
Daily label regimen versus case-by-case post-HD institutional dosing

The label mirror uses a daily renal regimen with a timing-dependent post-HD supplement. UCSF also offers a selected post-HD-only strategy, with toxicity, age and low-weight qualifications. The source renal units and exactly-30 boundary do not align automatically.

Before applying: Use one complete protocol with the dialysis prescription and ID/pharmacy review. Do not add the label supplement to an institutional post-HD dose or silently equate indexed and unindexed clearance.

Exactly six hours before HD: overlapping source wording

The label mirror says a supplement is needed within six hours but not needed when the dose is at least six hours before dialysis. The boundary is overlapping as printed.

Before applying: Clarify the timing endpoint with the controlling product label and dialysis pharmacist. Do not round an administration time to decide which instruction applies.

Also check: Daily label regimen versus case-by-case post-HD institutional dosing; Exactly six hours before HD: overlapping source wording

Rxlist source

GlobalRPh RX List - INVANZ

Product / population
Adult parenteral ertapenem; selected label renal/HD instructions. Pediatric renal doses are not established here.
Renal measure
Source prints CrCl mL/min/1.73 m2 but supplies unindexed Cockcroft-Gault formula; reconcile method.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Product page independently located after index-link resolver failure; exact index destination remains unverified.

Renal dosing, restrictions and evidence limits

At the source-printed CrCl threshold of 30 mL/min/1.73 m2 or less, adults receive 500 mg daily; above 30 no renal reduction is required. If 500 mg was given within six hours before hemodialysis, give 150 mg afterward. The same source says no supplement when administered at least six hours beforehand, leaving exactly six hours ambiguous. Pediatric renal, peritoneal-dialysis and hemofiltration data are absent. The formula/units mismatch also needs clarification.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/invanz-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - INVANZ

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult parenteral ertapenem; selected label renal/HD instructions. Pediatric renal doses are not established here.

Renal method: Source prints CrCl mL/min/1.73 m2 but supplies unindexed Cockcroft-Gault formula; reconcile method.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
Professional guidance

UCSF - ertapenem

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

Sunnybrook - ertapenem renal and replacement-therapy schedule

Adult institutional ertapenem guidance.

Renal method: CrCl in mL/min; HD, PD, CRRT and SLED distinguished.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF adult ertapenem renal and dialysis guidance

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

UCSF adult institutional ertapenem: non-dialysis, intermittent HD and continuous HD. Not universal CRRT guidance.

Renal method: CrCl mL/min; modality-specific institutional schedules.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 2 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

professional protocol difference

Daily label regimen versus case-by-case post-HD institutional dosing

The label mirror uses a daily renal regimen with a timing-dependent post-HD supplement. UCSF also offers a selected post-HD-only strategy, with toxicity, age and low-weight qualifications. The source renal units and exactly-30 boundary do not align automatically.

How to use this: Use one complete protocol with the dialysis prescription and ID/pharmacy review. Do not add the label supplement to an institutional post-HD dose or silently equate indexed and unindexed clearance.

GlobalRPh RX List - INVANZUCSF adult ertapenem renal and dialysis guidance

Source-specific interpretation; independent clinician adjudication pending.

threshold ambiguity

Exactly six hours before HD: overlapping source wording

The label mirror says a supplement is needed within six hours but not needed when the dose is at least six hours before dialysis. The boundary is overlapping as printed.

How to use this: Clarify the timing endpoint with the controlling product label and dialysis pharmacist. Do not round an administration time to decide which instruction applies.

GlobalRPh RX List - INVANZ

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - INVANZUCSF - ertapenemSunnybrook - ertapenem renal and replacement-therapy scheduleUCSF adult ertapenem renal and dialysis guidance
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The source uses indexed renal thresholds but prints an unindexed Cockcroft-Gault formula; preserve the distinction rather than silently treating the units as equivalent.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/ertapenem/

Usual Dosing (Adults)

Age >=13 years: 1 g once daily. Age 3 months to 12 years: 15 mg/kg twice daily, maximum 1 g/day. May administer IV for up to 14 days or IM for up to 7 days; IV infusion over 30 minutes. IM is an alternative where appropriate. DO NOT MIX OR CO-INFUSE WITH OTHER MEDICATIONS. DO NOT USE DEXTROSE DILUENTS.

Source treatment guidelines for normal renal function (CrCl >90 mL/min/1.73 m2) and body weight use these age-specific doses:

IndicationTotal antimicrobial duration
Complicated intra-abdominal5 to 14 days
Complicated skin/skin structure including diabetic foot7 to 14 days; adult diabetic-foot patients in source received up to 28 days parenteral or parenteral plus oral switch
Community-acquired pneumonia10 to 14 days
Complicated urinary tract including pyelonephritis10 to 14 days
Acute pelvic infection including postpartum endomyometritis, septic abortion, postoperative gynecologic3 to 10 days

Pneumonia/UTI durations can include oral stepdown after at least 3 days of parenteral therapy and demonstrated improvement.

Elective colorectal surgery prophylaxis in adults: 1 g IV once 1 hour before incision.

GRPH-ertapenem-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

Adults: CrCl >30 mL/min/1.73 m2, no adjustment. CrCl <=30, including ESRD <=10: 500 mg daily. No pediatric renal-insufficiency data.

GRPH-ertapenem-02 · Source section: Renal DosingRenal section finder

Hemodialysis

If the adult daily 500 mg dose is administered within 6 hours before HD, give an additional 150 mg after HD. If given at least 6 hours before HD, no supplement is needed. No data for peritoneal dialysis, hemofiltration, or pediatric HD.

When only serum creatinine is available, use a steady-state value. Source formula: male CrCl = weight (kg) x (140 - age in years) / [72 x serum creatinine (mg/100 mL)]; female result = male result x 0.85.

GRPH-ertapenem-03 · Source section: HemodialysisRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - INVANZ

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult parenteral ertapenem; selected label renal/HD instructions. Pediatric renal doses are not established here.

Renal method: Source prints CrCl mL/min/1.73 m2 but supplies unindexed Cockcroft-Gault formula; reconcile method.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

At the source-printed CrCl threshold of 30 mL/min/1.73 m2 or less, adults receive 500 mg daily; above 30 no renal reduction is required. If 500 mg was given within six hours before hemodialysis, give 150 mg afterward. The same source says no supplement when administered at least six hours beforehand, leaving exactly six hours ambiguous. Pediatric renal, peritoneal-dialysis and hemofiltration data are absent. The formula/units mismatch also needs clarification.

RDM43-rxlist-ertapenem-afd03f03bc-C1 · Source locator: Selected Dosage / Renal Impairment / Warnings sections; see source-specific qualifications in this summary.

Source-specific limits

Product page independently located after index-link resolver failure; exact index destination remains unverified.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/invanz-drug/
Retrieved
2026-09-07
Renal-function method
Source prints CrCl mL/min/1.73 m2 but supplies unindexed Cockcroft-Gault formula; reconcile method.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
75465f741f8413d55cb2d362552b1bd69c03ba261274816c0d72d46212f0862f
Separate professional-source layer

University and professional protocols

Professional

UCSF - ertapenem

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

IV dosing: CrCl >30 mL/min, 1 g daily; <30, 500 mg daily. The website does not allocate the exact value 30 between these displayed columns; do not invent an inclusive boundary.

IHD: 500 mg initially, then every evening. An alternative is 500 mg to 1 g initially and after subsequent HD sessions, selected case by case with ID pharmacy because toxicity risk matters. Advanced age or weight below 40 kg favors considering 500 mg in that alternative schedule. CVVHD: 1 g daily.

RDM30-005-ertapenem-1 · Source locator: UCSF - ertapenem; renal/dosing sections and stated qualifiers

Source-specific limits

The exact CrCl 30 boundary is incomplete in the website table. Apply an exact current label or an adjudicated institutional rule, not an inferred boundary.

Source identity and provenance
Source
https://idmp.ucsf.edu/content/ertapenem
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
7a53994666e7e8afb40a502a8e97f833d0a3f9db09724d8bbd7bad776908350a
Professional

Sunnybrook - ertapenem renal and replacement-therapy schedule

Open original reference

Open / share this exact local source

Sunnybrook Health Sciences Centre, Canada · Adult institutional ertapenem guidance.

Renal method: CrCl in mL/min; HD, PD, CRRT and SLED distinguished.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Source recheck unresolved. Prior follow-up retrieval/version warning retained; not resolved by v6.0. Read source-review status

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Usual 1 g daily is retained at CrCl 30-49 mL/min and during CRRT. At 10-29, below 10, PD or HD: 500 mg daily; on HD days give toward session end. SLED days use 1 g IV daily, with the ESRD schedule on non-dialysis days. This Canadian institutional protocol is not U.S. labeling.

RDM30-064-ertapenem-1 · Source locator: Sunnybrook - ertapenem renal and replacement-therapy schedule; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://sunnybrook.ca/antimicrobial-stewardship/renal-dosing-and-insufficiency-drug-dosing-considerations/
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min; HD, PD, CRRT and SLED distinguished.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
2a8503af70040e5866b9f3cf9e5b89f3b3278e18512bd771818d0b00cb3aa47d
Professional

UCSF adult ertapenem renal and dialysis guidance

Open original reference

Open / share this exact local source

University of California San Francisco · UCSF adult institutional ertapenem: non-dialysis, intermittent HD and continuous HD. Not universal CRRT guidance.

Renal method: CrCl mL/min; modality-specific institutional schedules.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

UCSF lists 1 g IV every 24 hours above CrCl 30 and 500 mg every 24 hours below 30; exactly 30 is not assigned by its printed inequalities. Intermittent HD: 500 mg once now, then each evening; alternatively 500 mg to 1 g once now, then after HD. The post-HD-only strategy is case-by-case because of toxicity risk; consider 500 mg in advanced age or body weight under 40 kg and consult ID pharmacy. Continuous HD: 1 g every 24 hours. Do not generalize that row to all CRRT prescriptions.

RDM43-professional-ertapenem-b0bd191d14-C1 · Source locator: Adult non-dialysis and intermittent/continuous hemodialysis tables; post-HD footnote.

Source identity and provenance
Source family
professional_guidance
Source
https://idmp.ucsf.edu/content/ertapenem
Retrieved
2026-09-07
Renal-function method
CrCl mL/min; modality-specific institutional schedules.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
ed30af8abe5571ed53cac130d078961b728e4f1fe4f4a5ee00b7b0aa26282507

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 3 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/ertapenem/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
0e2fb0b11f0201f35c729c2069cc086bdb9166d1966e5f0df9b143a4f6c7e51f
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report